Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex

Brain Research

Volumn 1023, Issue 1, 2004, Pages 134-140

  Muschamp, John W ^a   Regina, Meredith J ^a   Hull, Elaine M ^a   Winter, Jerrold C ^a   Rabin, Richard A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

5 HT 2A receptor; DOM; Glutamate; Hallucinogen; In vivo microdialysis; LSD; Prefrontal cortex

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; GLUTAMIC ACID; LYSERGIDE; PHENETHYLAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A ANTAGONIST;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; INFUSION; INTERMETHOD COMPARISON; MICRODIALYSIS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN SECRETION; RAT;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ANIMALS; EXTRACELLULAR FLUID; GLUTAMIC ACID; LYSERGIC ACID DIETHYLAMIDE; MALE; PREFRONTAL CORTEX; RATS; RATS, INBRED F344; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 4444279368     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.07.044     Document Type: Article

References (61)

1. H.D. Abraham, A.M. Aldridge, and P. Gogia The psychopharmacology of hallucinogens Neuropsychopharmacology 14 1996 285 298
2. B.W. Adams, and B. Moghaddam Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex Biol. Psychiatry 50 2001 750 757
3. G.K. Aghajanian, and O.H. Bing Persistence of lysergic acid diethylamide in the plasma of human subjects Clin. Pharmacol. Ther. 10 1964 611 614
4. G.K. Aghajanian, and G.J. Marek Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells Neuropharmacology 36 1997 589 599
5. G.K. Aghajanian, and G.J. Marek Serotonin and hallucinogens Neuropsychopharmacology 21 1999 16S 23S
6. G.K. Aghajanian, and G.J. Marek Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release Brain Res. 825 1999 161 171
7. G.K. Aghajanian, and G.J. Marek Serotonin model of schizophrenia: emerging role of glutamate mechanisms Brain Res. Brain Res. Rev. 31 2000 302 312
8. A. Araque, V. Parpura, R.P. Sanzgiri, and P.G. Haydon Tripartite synapses: glia, the unacknowledged partner Trends Neurosci. 22 1999 208 215
9. V.L. Arvanov, X. Liang, P. Magro, R. Roberts, and R.Y. Wang A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A,2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex Eur. J. Neurosci. 11 1999 2917 2934
10. V.L. Arvanov, X. Liang, A. Russo, and R.Y. Wang LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor- mediated transmission in the rat prefrontal cortex Eur. J. Neurosci. 11 1999 3064 3072
11. R.L. Balster, and J. Willetts Phencyclidine: a drug of abuse and a tool for neuroscience research C.R. Shuster M.J. Kuhar Pharmacological Aspects of Drugs Dependence: Towards an Integrated Neurobehavioral Approach 1990 Springer Berlin 233 262
12. L.H. Brauer, A.J. Goudie, and H. de Wit Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data Psychopharmacology (Berl.) 130 1997 2 13
13. G.R. Breese, D.J. Knapp, and S.S. Moy Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness Neurosci. Biobehav. Rev. 26 2002 441 455
14. R.G. Browne, and B.T. Ho Role of serotonin in the discriminative stimulus properties of mescaline Pharmacol. Biochem. Behav. 3 1975 429 435
15. D.R. Burt, I. Creese, and S.H. Snyder Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain Mol. Pharmacol. 12 1976 631 638
16. A. Carlsson, N. Waters, S. Holm-Waters, J. Tedroff, M. Nilsson, and M.L. Carlsson Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence Annu. Rev. Pharmacol. Toxicol. 41 2001 237 260
17. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237
18. V. Cornea-Hebert, M. Riad, C. Wu, S.K. Singh, and L. Descarries Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat J. Comp. Neurol. 409 1999 187 209
19. V. Cornea-Hebert, K.C. Watkins, B.L. Roth, W.K. Kroeze, P. Gaudreau, N. Leclerc, and L. Descarries Similar ultrastructural distribution of the 5-HT(2A) serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat Neuroscience 113 2002 23 35
20. R. Dall'Olio, R. Gaggi, V. Bonfante, and O. Gandolfi The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function Behav. Pharmacol. 10 1999 63 71
21. B. Dean, T. Hussain, W. Hayes, E. Scarr, S. Kitsoulis, C. Hill, K. Opeskin, and D.L. Copolov Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex J. Neurochem. 72 1999 1593 1599
22. D. Fiorella, S. Helsley, D.S. Lorrain, R.A. Rabin, and J.C. Winter The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs: III. The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion Psychopharmacology (Berl.) 121 1995 364 372
23. D. Fiorella, P.A. Palumbo, R.A. Rabin, and J.C. Winter The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents Psychopharmacology (Berl.) 119 1995 239 245
24. D. Fiorella, R.A. Rabin, and J.C. Winter The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs: I. Antagonist correlation analysis Psychopharmacology (Berl.) 121 1995 347 356
25. J.C. Gewirtz, and G.J. Marek Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors Neuropsychopharmacology 23 2000 569 576
26. R.A. Glennon, R. Young, J.M. Jacyno, M. Slusher, and J.A. Rosecrans DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines Eur. J. Pharmacol. 86 1983 453 459
27. R.A. Glennon, M. Titeler, and J.D. McKenney Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents Life Sci. 35 1984 2505 2511
28. I.D. Hirschhorn, and J.C. Winter Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli Psychopharmacologia 22 1971 64 71
29. L.E. Hollister, M.F. Macnicol, and H.K. Gillespie An hallucinogenic amphetamine analog (DOM) in man Psychopharmacologia 14 1969 62 73
30. R.L. Jakab, and P.S. Goldman-Rakic 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites Proc. Natl. Acad. Sci. U. S. A. 95 1998 735 740
31. H.S. Kim, I.S. Park, and W.K. Park NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice Life Sci. 63 1998 2305 2311
32. A. Klodzinska, M. Bijak, K. Tokarski, and A. Pilc Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice Pharmacol. Biochem. Behav. 73 2002 327 332
33. E.K. Lambe, and G.K. Aghajanian The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex J. Neurosci. 21 2001 9955 9963
34. D.S. Lorrain, C.S. Baccei, L.J. Bristow, J.J. Anderson, and M.A. Varney Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 Neuroscience 117 2003 697 706
35. R. Martin-Ruiz, M.V. Puig, P. Celada, D.A. Shapiro, B.L. Roth, G. Mengod, and F. Artigas Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism J. Neurosci. 21 2001 9856 9866
36. T. Meert, and I. Stolerman Drug discrimination in behavioral neuroscience Pharmacol. Biochem. Behav. 64 1999 191 453
37. R. Meller, P.J. Harrison, J.M. Elliott, and T. Sharp In vitro evidence that 5-hydroxytryptamine increases efflux of glial glutamate via 5-HT(2A) receptor activation J. Neurosci. Res. 67 2002 399 405
38. H.Y. Meltzer The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 1999 106S 115S
39. L.A. Miner, J.R. Backstrom, E. Sanders-Bush, and S.R. Sesack Ultrastructural localization of serotonin(2A) receptors in the middle layers of the rat prelimbic prefrontal cortex Neuroscience 116 2003 107 117
40. B. Moghaddam, and B.W. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 1998 1349 1352
41. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J. Neurosci. 17 1997 2921 2927
42. V. Parpura, and P.G. Haydon Physiological astrocytic calcium levels stimulate glutamate release to modulate adjacent neurons Proc. Natl. Acad. Sci. U. S. A. 97 2000 8629 8634
43. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 4th edn. 1998 Academic Press New York
44. M.V. Puig, P. Celada, L. Diaz-Mataix, and F. Artigas In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents Cereb. Cortex 13 2003 870 882
45. D.J. Sanger, J. Benavides, G. Perrault, E. Morel, C. Cohen, D. Joly, and B. Zivkovic Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes Neurosci. Biobehav. Rev. 18 1994 355 372
46. R. Schreiber, M. Brocco, and M.J. Millan Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone Eur. J. Pharmacol. 264 1994 99 102
47. C. Schuster, and C. Johanson Relationship between the discriminative stimulus properties and subjective effects of drugs F. Colpaert R. Balster Transduction Mechanisms of Drug Stimuli 1988 Springer Berlin 161 175
48. J.L. Scruggs, S. Patel, M. Bubser, and A.Y. Deutch DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons J. Neurosci. 20 2000 8846 8852
49. J.L. Scruggs, D. Schmidt, and A.Y. Deutch The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats Neurosci. Lett. 346 2003 137 140
50. A.T. Shulgin, and A. Shulgin PiHKAL: A Chemical Love Story 1991 Transform Press Berkeley 637 642
51. S.H. Snyder, L.A. Faillace, and H. Weingartner DOM (STP), a new hallucinogenic drug, and DOET: effects in normal subjects Am. J. Psychiatry 125 1968 113 120
52. F.X. Vollenweider, M.F. Vollenweider-Scherpenhuyzen, A. Babler, H. Vogel, and D. Hell Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action NeuroReport 9 1998 3897 3902
53. J.G. Wagner, G.K. Aghajanian, and O.H. Bing Correlation of performance test scores with "tissue concentration" of lysergic acid diethylamide in human subjects Clin. Pharmacol. Ther. 9 1968 635 638
54. J.C. Winter Hallucinogens as discriminative stimuli Fed. Proc. 33 1974 1825 1832
55. J.C. Winter Blockade of the stimulus properties of mescaline by a serotonin antagonist Arch. Int. Pharmacodyn. Ther. 214 1975 250 253
56. J.C. Winter Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine J. Pharmacol. Exp. Ther. 204 1978 416 423
57. J.C. Winter Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus Psychopharmacology (Berl.) 68 1980 159 162
58. J.C. Winter, and R.A. Rabin Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus Pharmacol. Biochem. Behav. 30 1988 617 624
59. J.C. Winter, M. Doat, and R.A. Rabin Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia Life Sci. 68 2000 337 344
60. J.C. Winter, J.R. Eckler, and R.A. Rabin Serotonergic/glutamatergic interactions: the effects of mGlu(2/3) receptor ligands in rats trained with LSD and PCP as discriminative stimuli Psychopharmacology (Berl.) 172 2004 233 240
61. Z.-X. Xi, D.A. Baker, H. Shen, D.S. Carson, and P.W. Kalivas Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens J. Pharmacol. Exp. Ther. 300 2002 162 171